Viking Therapeutics (VKTX) Retained Earnings (2014 - 2026)
Viking Therapeutics (VKTX) reported Retained Earnings of -$1.0 billion for Q1 2026, down 88.53% on a YoY basis from -$8.8 billion in Q1 2025, and down 18.68% sequentially from -$847.5 million in Q4 2025.
Viking Therapeutics (VKTX) Retained Earnings (2014 - 2026) Analysis & Trends
Viking Therapeutics (VKTX) has 13 years of Retained Earnings data on file, last reported at -$1.0 billion in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 88.53% year-over-year to -$1.0 billion; the trailing twelve-month figure through Mar 2026 stood at -$1.0 billion (down 88.53% YoY), and the FY2025 full-year result was -$847.5 million, down 73.71% from the prior year.
- Retained Earnings retreated to -$1.0 billion in Q1 2026, from -$847.5 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$239.3 million in Q1 2022 to a low of -$1.0 billion in Q1 2026.
- A 5-year average of -$463.7 million and a median of -$405.3 million in 2024 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings fell 28.06% in 2024 and tumbled 88.53% in 2026, its largest moves.
- Tracing VKTX's Retained Earnings over 5 years: stood at -$292.0 million in 2022, then decreased by 29.41% to -$377.9 million in 2023, then dropped by 29.1% to -$487.9 million in 2024, then tumbled by 73.71% to -$847.5 million in 2025, then decreased by 18.68% to -$1.0 billion in 2026.
- Business Quant data shows VKTX's Retained Earnings at -$1.0 billion in Q1 2026, -$847.5 million in Q4 2025, and -$689.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Viking Therapeutics | 4.09 Bn | 4.09 Bn | - | -1.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.01 Bn |
| Dec 31, 2025 | -847.55 Mn |
| Sep 30, 2025 | -689.88 Mn |
| Jun 30, 2025 | -599.10 Mn |
| Mar 31, 2025 | -533.54 Mn |
| Dec 31, 2024 | -487.91 Mn |
| Sep 30, 2024 | -452.49 Mn |
| Jun 30, 2024 | -427.55 Mn |
| Mar 31, 2024 | -405.30 Mn |
| Dec 31, 2023 | -377.94 Mn |
| Sep 30, 2023 | -353.34 Mn |
| Jun 30, 2023 | -330.81 Mn |
| Mar 31, 2023 | -311.58 Mn |
| Dec 31, 2022 | -292.05 Mn |
| Sep 30, 2022 | -272.49 Mn |
| Jun 30, 2022 | -256.72 Mn |
| Mar 31, 2022 | -239.29 Mn |
| Dec 31, 2021 | -223.18 Mn |
| Sep 30, 2021 | -210.83 Mn |
| Jun 30, 2021 | -197.58 Mn |